The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.
Rocio Garcia-Carbonero
Consultant or Advisory Role - Amgen; Merck; Roche
Honoraria - Amgen; Merck; Roche
Research Funding - Merck
Fernando Rivera
Research Funding - Lilly
Juan Maurel
No relevant relationships to disclose
Jean-Pierre M. Ayoub
Research Funding - ImClone Systems
Malcolm J. Moore
Research Funding - ImClone Systems; Lilly
Andres Cervantes-Ruiperez
No relevant relationships to disclose
Timothy R. Asmis
Consultant or Advisory Role - ImClone Systems
Honoraria - ImClone Systems
Jonathan D. Schwartz
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Shaila Ballal
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
Josep Tabernero
Consultant or Advisory Role - ImClone Systems